CN102753704A - I型干扰素诊断 - Google Patents

I型干扰素诊断 Download PDF

Info

Publication number
CN102753704A
CN102753704A CN2010800447566A CN201080044756A CN102753704A CN 102753704 A CN102753704 A CN 102753704A CN 2010800447566 A CN2010800447566 A CN 2010800447566A CN 201080044756 A CN201080044756 A CN 201080044756A CN 102753704 A CN102753704 A CN 102753704A
Authority
CN
China
Prior art keywords
ifn
ifi27
ifi44l
ifi44
rsad2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800447566A
Other languages
English (en)
Chinese (zh)
Inventor
B·希格斯
朱蔚
C·莫尔豪斯
B·怀特
B·加莱
Y·姚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Publication of CN102753704A publication Critical patent/CN102753704A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2010800447566A 2009-09-03 2010-09-02 I型干扰素诊断 Pending CN102753704A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23963009P 2009-09-03 2009-09-03
US61/239,630 2009-09-03
PCT/US2010/047721 WO2011028933A1 (en) 2009-09-03 2010-09-02 Type 1 interferon diagnostic

Publications (1)

Publication Number Publication Date
CN102753704A true CN102753704A (zh) 2012-10-24

Family

ID=43649646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800447566A Pending CN102753704A (zh) 2009-09-03 2010-09-02 I型干扰素诊断

Country Status (23)

Country Link
US (3) US20120251546A1 (enExample)
EP (1) EP2473636B1 (enExample)
JP (2) JP5727484B2 (enExample)
KR (1) KR20120101340A (enExample)
CN (1) CN102753704A (enExample)
AU (1) AU2010289383B2 (enExample)
BR (1) BR112012004781A2 (enExample)
CA (1) CA2772921A1 (enExample)
CY (1) CY1118566T1 (enExample)
DK (1) DK2473636T3 (enExample)
ES (1) ES2613055T3 (enExample)
HR (1) HRP20170091T1 (enExample)
HU (1) HUE032917T2 (enExample)
LT (1) LT2473636T (enExample)
ME (1) ME02599B (enExample)
MX (1) MX2012002640A (enExample)
PL (1) PL2473636T3 (enExample)
PT (1) PT2473636T (enExample)
RS (1) RS55641B1 (enExample)
RU (1) RU2012112802A (enExample)
SI (1) SI2473636T1 (enExample)
SM (2) SMT201700063T1 (enExample)
WO (1) WO2011028933A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105567861A (zh) * 2016-03-16 2016-05-11 宫蕊 Ifi27作为冠心病诊断标志物的用途
CN113508138A (zh) * 2019-02-15 2021-10-15 阿斯利康(瑞典)有限公司 I型干扰素介导的障碍

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237889A1 (en) * 2002-06-11 2003-12-22 Idaho Research Foundation Type i interferon-inducible proteins to detect viral infection
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
JP2010526107A (ja) * 2007-05-03 2010-07-29 メディミューン，エルエルシー 自己免疫疾患の自己抗体マーカー
EP2701742A4 (en) * 2011-04-26 2015-03-18 Genentech Inc COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US9493570B2 (en) * 2012-06-13 2016-11-15 Medimmune, Llc Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
JP6531306B2 (ja) * 2015-02-20 2019-06-19 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN105316404B (zh) * 2015-02-27 2017-02-22 中南大学湘雅二医院 系统性红斑狼疮生物标志物及其诊断试剂盒
MX2018010771A (es) 2016-03-10 2019-05-15 Viela Bio Inc Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
EP4058060B1 (en) 2019-11-11 2025-02-19 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
EP4566667A3 (en) 2020-05-29 2025-09-03 AstraZeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
CN116234553A (zh) * 2020-10-02 2023-06-06 新基公司 治疗系统性红斑狼疮的方法和作为对疗法临床敏感性的预测指标的生物标志物的用途
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
AU2021383537A1 (en) 2020-11-18 2023-06-29 Astrazeneca Ab Steroid sparing
PL4192882T3 (pl) 2021-04-23 2025-04-28 Astrazeneca Ab Leczenie toczniowego zapalenia nerek przeciwciałem przeciwko receptorowi typu i inf anifrolumabem
EP4326322A1 (en) 2021-04-23 2024-02-28 Astrazeneca AB Treatment of cutaneous lupus erythematous
KR20250092298A (ko) 2021-04-23 2025-06-23 아스트라제네카 아베 피하 주사용 항-ifnar1 투여 요법
EP4333877A1 (en) * 2021-05-04 2024-03-13 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
EP4337696A1 (en) 2021-05-12 2024-03-20 Astrazeneca AB Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
CA3226744A1 (en) 2021-07-27 2023-02-02 Astrazeneca Ab Treatment of lupus
KR20240082399A (ko) 2021-10-04 2024-06-10 아스트라제네카 아베 루푸스의 치료
AU2023339761A1 (en) 2022-09-14 2025-03-20 Viatris Asia Pacific Pte. Ltd. S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
JP2025533978A (ja) 2022-10-13 2025-10-09 アストラゼネカ・アクチエボラーグ ループスの治療
WO2024241156A1 (en) 2023-05-19 2024-11-28 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092890A1 (en) * 2005-08-05 2007-04-26 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
WO2008070137A2 (en) * 2006-12-06 2008-06-12 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US7247425B2 (en) * 1998-01-30 2007-07-24 Evolutionary Genomics, Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2004293369A1 (en) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
CN1795010A (zh) 2003-04-23 2006-06-28 梅达雷克斯公司 针对α干扰素受体－1(IFNAR－1)的人源化抗体
SI2418220T1 (sl) 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alfa protitelesa in njihova uporaba
EP1730308A4 (en) * 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
PT1781705E (pt) 2004-06-21 2014-12-23 Medarex Llc Anticorpos contra recetor i do interferão alfa e as suas utilizações
US8211649B2 (en) * 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
WO2008016356A2 (en) * 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
JP2010526107A (ja) * 2007-05-03 2010-07-29 メディミューン，エルエルシー 自己免疫疾患の自己抗体マーカー
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
CA2714410A1 (en) * 2008-02-08 2009-08-13 Medimmune, Llc Disease markers and uses thereof
WO2009130176A1 (en) * 2008-04-21 2009-10-29 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antiviral Therapy
US20090325176A1 (en) * 2008-06-05 2009-12-31 Wyeth Gene Expression Profiles Associated with Asthma Exacerbation Attacks

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092890A1 (en) * 2005-08-05 2007-04-26 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
WO2008070137A2 (en) * 2006-12-06 2008-06-12 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105567861A (zh) * 2016-03-16 2016-05-11 宫蕊 Ifi27作为冠心病诊断标志物的用途
CN105567861B (zh) * 2016-03-16 2018-12-14 宫蕊 Ifi27作为冠心病诊断标志物的用途
CN113508138A (zh) * 2019-02-15 2021-10-15 阿斯利康(瑞典)有限公司 I型干扰素介导的障碍

Also Published As

Publication number Publication date
CY1118566T1 (el) 2017-07-12
LT2473636T (lt) 2017-02-10
US20120251546A1 (en) 2012-10-04
BR112012004781A2 (pt) 2017-02-14
ES2613055T3 (es) 2017-05-22
PL2473636T3 (pl) 2017-05-31
EP2473636B1 (en) 2016-10-26
PT2473636T (pt) 2017-02-06
RS55641B1 (sr) 2017-06-30
RU2012112802A (ru) 2013-10-10
ME02599B (me) 2017-06-20
US20160024205A1 (en) 2016-01-28
CA2772921A1 (en) 2011-03-10
JP2013503642A (ja) 2013-02-04
DK2473636T3 (en) 2017-02-06
WO2011028933A1 (en) 2011-03-10
EP2473636A4 (en) 2013-02-27
AU2010289383B2 (en) 2015-04-16
JP5727484B2 (ja) 2015-06-03
EP2473636A1 (en) 2012-07-11
HRP20170091T1 (hr) 2017-03-24
AU2010289383A1 (en) 2012-04-19
MX2012002640A (es) 2012-06-25
HUE032917T2 (hu) 2017-11-28
JP2015147788A (ja) 2015-08-20
US20150191788A1 (en) 2015-07-09
SI2473636T1 (sl) 2017-04-26
SMT201700063T1 (it) 2017-03-08
SMT201700063B (it) 2017-03-08
KR20120101340A (ko) 2012-09-13

Similar Documents

Publication Publication Date Title
JP5727484B2 (ja) Ｉ型インターフェロン診断法
JP5411129B2 (ja) インターフェロンα誘導性薬力学的マーカー
KR101532797B1 (ko) 인터페론 알파 유도성 약력학적 마커
Yao et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus
CN101999001B (zh) 疾病标志物及其用途
AU2009240021B2 (en) Antiviral therapy
US20160208329A1 (en) Systems, devices and methods for anti-tl1a therapy
JP2013526845A (ja) サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ
EP2191274A1 (en) Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
CN101594882A (zh) 干扰素α诱导的药代动力学标记物
WO2009155559A1 (en) Interferon alpha-induced pharmacodynamic markers
EP4112746A1 (en) Method for predicting a clinical response towards an immune checkpoint inhibitor based on pretreatment therewith
HK1140406A (en) Interferon alpha-induced pharmacodynamic markers
HK1150063B (en) Disease markers and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121024